

Horizon, Swift partnership, 1/16

January 2016—Swift Biosciences will incorporate Horizon Discovery Group's human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.

The Accel-Amplicon 56G Oncology Panel is a single tube assay that offers comprehensive and hot-spot coverage of 56 clinically relevant oncology-related genes, using a 263-amplicon design to generate multiplex libraries compatible with commonly used NGS platforms. The panel has been designed for compatibility with the short DNA fragments from both formalin-fixed, paraffin-embedded and circulating, cell-free DNA samples.

Swift will include Horizon's HDx Quantitative Multiplex Reference Standard material as a positive control in its trial-size oncology panel, allowing users to validate the panel for use for next-generation sequencing applications in their lab.

[**Horizon Discovery**](#), +44 (0) 1223 655 580

[**Swift Biosciences**](#), 734-330-2568